Sale!

Tirzepatide 5mg

Original price was: 74,78 €.Current price is: 65,47 €.

Tirzepatide is an innovative pharmacological agent that represents a significant advancement in the treatment of type 2 diabetes mellitus (T2DM) and obesity. This medication is a dual agonist that targets both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. These incretin hormones are naturally occurring peptides involved in the regulation of glucose homeostasis and energy balance.

Category:

Description

Tirzepatide is an innovative pharmacological agent that represents a significant advancement in the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is a dual agonist that targets both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. These incretin hormones are naturally occurring peptides involved in the regulation of glucose homeostasis and energy balance. By simultaneously targeting these pathways, tirzepatide exerts a synergistic effect that enhances its efficacy in controlling hyperglycemia and promoting weight loss, distinguishing it from existing therapies that typically only target the GLP-1 receptor.

The development of tirzepatide is based on the growing recognition that more effective therapeutic options are needed for patients with T2DM, particularly those who also struggle with obesity. Traditional antidiabetic drugs often fail to adequately meet the diverse needs of these patients, particularly regarding weight management, which is a crucial component of comprehensive diabetes care. The dual mechanism of tirzepatide not only addresses glucose control but also has significant implications for body weight, an area where many other therapies have had only limited success. The drug’s ability to achieve such significant outcomes has led to it being considered a potential turning point in both endocrinology and the management of metabolic disorders.

Recent clinical trials have highlighted the remarkable efficacy of tirzepatide. For example, the SURPASS program, a series of Phase III clinical trials, demonstrated that tirzepatide achieved superior reductions in HbA1c levels and body weight compared to other established therapies, including insulin and GLP-1 receptor agonists like semaglutide. The dual incretin agonism of tirzepatide offers a more comprehensive approach to T2DM and obesity, making it particularly attractive for patients who need both glycemic control and significant weight loss. Furthermore, the drug’s effects extend beyond these primary outcomes, potentially offering benefits for cardiovascular health and the overall metabolic profile, making it an attractive option not only for diabetologists but also for cardiologists and endocrinologists.

Given the growing global epidemic of obesity and diabetes, the introduction of tirzepatide comes at the right time. Its potential to address the dual challenges of hyperglycemia and obesity could redefine the standard of care for millions of patients worldwide. Moreover, its off-label use is already being explored in the bodybuilding and fitness community, where its potent weight loss effects could offer an advantage in fat reduction and metabolic optimization. However, the full spectrum of tirzepatide’s potential is still being investigated, and ongoing research is likely to further expand our understanding of its benefits and applications.

Main effects and benefits

Weight loss

It has been shown that tirzepatide produces unprecedented weight loss in clinical trials, which is particularly remarkable given the historical difficulty of achieving significant weight reductions in patients with T2DM or obesity. In the SURMOUNT-1 trial, a Phase III study focused on weight loss, participants treated with the highest dose of tirzepatide (15 mg) achieved an average weight loss of 22.5% after 72 weeks. This is a significant improvement over the weight losses achieved with other anti-obesity medications, including semaglutide, which typically achieve weight reductions of about 15-17%. The weight loss effect of tirzepatide is attributed to its dual action on GIP and GLP-1 receptors, which together increase satiety, reduce food intake, and increase energy expenditure.

For bodybuilders and fitness enthusiasts, this weight loss effect is of particular interest, as it can help achieve a leaner physique with reduced body fat while preserving muscle mass. This is crucial in contexts where maintaining muscle definition and overall body composition is of paramount importance. Furthermore, the reduction of visceral fat, which is often resistant to diet and exercise alone, is another significant advantage, as visceral fat is associated with an increased cardiometabolic risk.

Glycemic control

The efficacy of tirzepatide in lowering blood sugar levels is another major benefit. In clinical trials, the drug has consistently shown superior HbA1c reductions compared to other treatments. For example, in the SURPASS-2 trial, tirzepatide at a dose of 15 mg reduced HbA1c by 2.58% from baseline, while semaglutide achieved a reduction of 2.07%. This superior glycemic control is crucial for patients with T2DM, as maintaining low HbA1c levels reduces the risk of complications such as neuropathy, nephropathy, and retinopathy.

For athletes and bodybuilders, maintaining stable blood sugar levels is crucial for optimizing performance, recovery, and overall metabolic health. The ability of tirzepatide to provide robust glycemic control without significantly increasing the risk of hypoglycemia (thanks to its glucose-dependent mechanism) makes it a particularly attractive option for those who need strict control of their blood sugar levels.

Cardiovascular benefits

Beyond its effects on weight and glucose levels, tirzepatide may also offer cardiovascular benefits. The drug has been shown to reduce several cardiovascular risk factors, including body weight, systolic blood pressure, and lipid levels. These effects are particularly relevant for patients with T2DM, who have an increased risk of cardiovascular disease. Although long-term studies on cardiovascular outcomes are still ongoing, early data suggest that tirzepatide could play a role in reducing cardiovascular events, such as heart attacks and strokes, in high-risk populations.

Mechanism of action

The mechanism of action of tirzepatide is unique due to its dual agonism at both the GIP and GLP-1 receptors, which are central to glucose metabolism and energy balance.

GIP receptor agonism

GIP is an incretin hormone released by the K cells of the small intestine in response to nutrient intake, particularly fats and carbohydrates. Its main function is to enhance insulin secretion from the beta cells of the pancreas in a glucose-dependent manner. However, GIP also plays a role in lipid metabolism and adipogenesis. By agonizing the GIP receptor, tirzepatide enhances insulin secretion in response to meals, which helps control postprandial blood sugar levels. This insulinotropic effect is crucial for the management of T2DM, as it reduces hyperglycemia without significantly increasing the risk of hypoglycemia, a common concern with other insulinotropic agents.

Interestingly, GIP receptor agonism also affects lipid metabolism. In preclinical studies, GIP has been shown to promote lipid storage in adipose tissue, but in the context of tirzepatide’s dual action, this effect may be counterbalanced by the activation of the GLP-1 receptor, which promotes weight loss. The net effect is a reduction in body fat, particularly visceral fat, which is associated with improved metabolic health.

The process of GIP (gastric inhibitory polypeptide / glucose-dependent insulinotropic polypeptide) secretion and its enhanced synthesis in response to a high-fat diet (HFD) involves several key mechanisms. Fatty acid-binding protein 5 (FABP5) and G-protein-coupled receptor 120 (GPR120) are crucial for the immediate secretion of GIP following fat intake. Additionally, in the context of obesity induced by HFD, the transcription factor regulatory factor X6 (Rfx6) plays a significant role in the hypersecretion of GIP by upregulating the expression of the GIP gene. These processes are linked to other components such as GPCRs (G-protein-coupled receptors) and Pdx-1 (pancreatic and duodenal homeobox 1).

GLP-1 receptor agonism

GLP-1, another incretin hormone, is secreted by the L cells of the intestine in response to food intake. It enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety. GLP-1 receptor agonists have become a central component in the treatment of T2DM, as they lower blood sugar levels while simultaneously promoting weight loss. Tirzepatide’s action on the GLP-1 receptor significantly contributes to its effects on satiety and weight reduction. By slowing gastric emptying, tirzepatide prolongs the feeling of satiety after meals, thereby reducing overall calorie intake. Additionally, the suppression of glucagon, a hormone that raises blood sugar levels, supports the maintenance of glycemic control.

The dual activation of GIP and GLP-1 receptors by tirzepatide leads to a synergistic effect that enhances its therapeutic potential. While GLP-1 receptor agonism is primarily responsible for the observed weight loss and appetite suppression by tirzepatide, GIP receptor agonism complements these effects by further enhancing insulin secretion and influencing lipid metabolism. This combination allows tirzepatide to address both hyperglycemia and obesity more effectively than agents that target only one of these pathways.

Pancreatic and extrapancreatic functions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). GIP acts directly on the endocrine pancreas, bone, adipose tissue, the gastrointestinal tract, and the brain. GLP-1 acts directly on the endocrine pancreas, the gastrointestinal tract, the heart, and the brain.

Improvement of beta-cell function

Beyond improving insulin secretion, tirzepatide may also play a crucial role in preserving and improving the function of pancreatic beta cells. Chronic activation of GIP and GLP-1 receptors has been shown to promote beta-cell proliferation and reduce apoptosis, the programmed cell death that often contributes to the decline in beta-cell mass in T2DM. By supporting beta-cell survival and potentially their proliferation, tirzepatide could help maintain a healthier beta-cell population over time. This preservation is crucial for long-term glycemic control in patients with T2DM and could potentially delay disease progression, reduce the need for exogenous insulin, and mitigate the risk of diabetes-related complications.

Effects on hepatic glucose production

Tirzepatide’s ability to suppress glucagon secretion has significant implications for hepatic glucose production, a key factor in managing fasting glucose levels. By reducing glucagon levels, tirzepatide decreases gluconeogenesis, the process by which the liver produces glucose from non-carbohydrate sources, and glycogenolysis, the breakdown of glycogen into glucose. Both processes significantly contribute to fasting glycemia in diabetes. This reduction in hepatic glucose production, combined with improved peripheral glucose uptake through increased insulin sensitivity, leads to more effective overall glucose control, particularly in lowering fasting glucose levels and smoothing out daily glucose fluctuations.

Modulation of lipid metabolism

In addition to its effects on glucose metabolism, tirzepatide plays a significant role in lipid metabolism, particularly in how the body handles dietary fats. By influencing the GIP pathway, tirzepatide could reduce the accumulation of triglycerides in adipose tissue, which is crucial since excess triglycerides, particularly in visceral fat, are associated with insulin resistance and an increased cardiovascular risk. Furthermore, tirzepatide could improve fat oxidation, the process by which fats are broken down for energy, contributing to weight loss and improved lipid profiles. These effects include reductions in LDL cholesterol and increases in HDL cholesterol, which further support the weight loss and cardiovascular benefits of tirzepatide therapy. For patients, these metabolic improvements can lead to a reduction in visceral fat, which is associated with better insulin sensitivity and a lower risk of metabolic syndrome, a cluster of conditions that increase the risk of heart disease, stroke, and diabetes.

Anti-inflammatory effects

Recent studies suggest that tirzepatide may also have anti-inflammatory properties, potentially mediated by the activation of the GLP-1 receptor. Chronic low-grade inflammation is a hallmark of metabolic disorders such as T2DM and obesity, and plays a significant role in the development of insulin resistance and cardiovascular complications. By reducing inflammatory cytokines such as C-reactive protein (CRP) and interleukins, tirzepatide could help mitigate this inflammation, thereby improving insulin sensitivity and lowering cardiovascular risk. Furthermore, tirzepatide could further improve cardiovascular health by enhancing endothelial function, which is often impaired in patients with diabetes and obesity. This reduction in inflammation and improvement in endothelial function offer additional protective benefits against cardiovascular disease and further enhance the therapeutic profile of tirzepatide.

Improvement of cardiovascular health

The effects of tirzepatide on cardiovascular health extend beyond its metabolic effects. The activation of GLP-1 receptors in vascular endothelial cells improves endothelial function, which is crucial for maintaining healthy blood vessels and reducing arterial stiffness, a common problem in patients with T2DM that contributes to hypertension and cardiovascular disease. By improving arterial elasticity and lowering blood pressure, tirzepatide could reduce the risk of cardiovascular complications such as stroke and heart attack. In combination with its effects on weight loss and improved glycemic control, tirzepatide represents a comprehensive treatment option to manage not only diabetes but also the associated cardiovascular risks, making it a highly versatile and effective therapeutic agent in the fight against metabolic disorders.

Comparison between tirzepatide and semaglutide

Tirzepatide and semaglutide are both incretin-based therapies, but they differ significantly in their mechanisms of action, efficacy, and potential applications.

Mechanism of action

Semaglutide is a GLP-1 receptor agonist that mimics the action of the endogenous hormone GLP-1, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety. Tirzepatide, on the other hand, is a dual GIP and GLP-1 receptor agonist, offering a broader mechanism of action that includes the effects of both incretin hormones. This dual agonism allows tirzepatide to have a more pronounced effect on both glucose metabolism and weight reduction compared to semaglutide.

Efficacy

The efficacy of tirzepatide compared to semaglutide in patients with type 2 diabetes was evaluated by measuring the reduction in glycated hemoglobin (HbA1c) and body weight after 40 weeks of treatment. The study used three different dosages of tirzepatide (5 mg, 10 mg, and 15 mg) and compared them with a standard dose of 1 mg semaglutide (doi: 10.1056/NEJMoa2107519).

Reduction in glycated hemoglobin (HbA1c):

  • All dosages of tirzepatide showed a greater reduction in HbA1c levels compared to semaglutide.
  • The 5 mg dose of tirzepatide led to an average HbA1c reduction of about 2.01%, which is more than the 1.86% reduction observed with semaglutide.
  • Higher doses of tirzepatide (10 mg and 15 mg) led to even more significant reductions, with decreases of 2.24% and 2.30%, respectively.

Reduction in body weight:

  • Tirzepatide also showed superior efficacy in weight reduction across all dosages compared to semaglutide.
  • Patients who received the 5 mg dose of tirzepatide lost an average of 7.6 kg, which is more than the 5.7 kg loss with semaglutide.
  • The 10 mg and 15 mg doses of tirzepatide led to even greater weight losses, with average losses of 9.3 kg and 11.2 kg, respectively.
  • Overall, tirzepatide was more effective than semaglutide in reducing HbA1c levels and promoting weight loss in patients with type 2 diabetes.

Applications

While both medications are used to treat T2DM, the additional effects of tirzepatide on weight loss make it a more versatile option for patients with obesity. Semaglutide is also approved for chronic weight management under the brand name Wegovy, but the superior efficacy of tirzepatide in weight loss could make it a preferred choice in this context once it is approved for this indication. Furthermore, the effects of tirzepatide on lipid metabolism and potential cardiovascular benefits could offer additional advantages in treating patients with metabolic syndrome or high cardiovascular risk.

Side effects

Both medications have similar side effect profiles, with gastrointestinal symptoms being the most common. However, the dual action of tirzepatide could lead to slightly different tolerability profiles that need to be further investigated to be fully understood. Long-term safety data are better established for semaglutide since it has been on the market longer, but early indications suggest that the safety profile of tirzepatide is comparable.

Uses

Tirzepatide is used for several important purposes, each with different goals and outcomes.

Management of type 2 diabetes

Tirzepatide is primarily indicated for the treatment of T2DM to achieve improved glycemic control. The dual mechanism of action of the drug allows it to lower HbA1c levels more effectively than many existing treatments, making it an ideal choice for patients who have difficulties achieving their glycemic goals with other medications. The combination of GIP and GLP-1 receptor agonism targets both fasting and postprandial hyperglycemia and reduces the risk of long-term complications associated with poor glycemic control, such as cardiovascular disease, neuropathy, and retinopathy.

The goal of using tirzepatide in T2DM is not only to lower HbA1c levels but also to improve overall metabolic health. By reducing body weight, lowering blood pressure, and improving lipid profiles, tirzepatide helps mitigate the broader metabolic risks associated with diabetes. For patients with obesity and T2DM, tirzepatide offers the dual benefit of glycemic control and significant weight loss, which can further improve insulin sensitivity and reduce the need for additional medications.

Weight management and obesity

Tirzepatide is being explored for its potential to treat obesity, even in patients without diabetes. The drug’s ability to induce significant weight loss makes it a promising candidate for combating the obesity epidemic, which is a major risk factor for numerous chronic diseases, including cardiovascular disease, certain cancers, and osteoarthritis. The goal of using tirzepatide in this context is to achieve sustainable weight loss that improves overall health outcomes, reduces comorbidities, and enhances quality of life.

In the context of obesity management, tirzepatide is particularly useful for patients who have not lost enough weight with lifestyle changes alone or who struggle with weight regain after initial success. The drug’s ability to reduce hunger and increase satiety supports adherence to a calorie-reduced diet, which is essential for long-term weight management. Furthermore, the weight loss achieved with tirzepatide is accompanied by improvements in metabolic parameters, such as a reduction in waist circumference, improved insulin sensitivity, and lower inflammatory markers, all of which contribute to better health outcomes ().

The graph shows that tirzepatide significantly reduced body weight by 18.4% to 21.1% at week 72, compared to a slight weight gain of 2.5% to 3.3% with placebo. This highlights tirzepatide as an effective treatment for significant weight loss.

The graph illustrates that participants who took tirzepatide experienced a significant and steady weight reduction, reaching a decrease of 21.1% by week 72. In contrast, those who took the placebo recorded a slight weight gain of 3.3% in the same period. The baseline weight of the participants was an average of 101.9 kg, highlighting the significant impact of tirzepatide on weight loss.

The graph shows the percentage change in body weight from the start of an intensive lifestyle intervention over a period of 72 weeks, comparing tirzepatide with a placebo. The tirzepatide group experienced a significant reduction in body weight, with an average decrease of 25.0% after 72 weeks, compared to a 4.8% decrease in the placebo group. The results suggest that tirzepatide is more effective than a placebo for long-term weight loss.

Off-label use in bodybuilding and fitness

Although tirzepatide is not officially approved for use in bodybuilding or fitness, it is gaining attention in these communities due to its potent effect on reducing body fat. Bodybuilders often aim to reduce body fat while simultaneously preserving or even building muscle mass, a goal that tirzepatide can support due to its strong effect on fat breakdown without significant muscle catabolism. The goal in this context is to improve body composition, reduce visceral fat, and increase metabolic efficiency, all of which contribute to better athletic performance and a defined physique.

However, the off-label use of tirzepatide in this context should be approached with caution, as the long-term effects of the drug in individuals without metabolic disorders are not yet fully understood.

Dosage, application, and precautions

Dosage

  • Start with a dose of 2.5 mg administered subcutaneously once weekly. This dose serves to initiate therapy and minimize gastrointestinal side effects.
  • After four weeks on the initial dose, the dosage should be increased to 5 mg once weekly.
  • If additional glycemic control is needed, further dose increases can be made in 2.5 mg increments at intervals of at least four weeks, up to a maximum dose of 15 mg once weekly.

Application

  • Injection sites: Tirzepatide should be injected subcutaneously into the abdomen, thigh, or upper arm. It is recommended to rotate the injection site with each administration to avoid irritation. The injection should not be given in areas where the skin is tender, bruised, red, or hard.
  • Time of administration: Tirzepatide can be administered at any time of day, with or without food. The day of the week for the injection can be changed, as long as the interval between doses is at least three days (72 hours).
  • Missed dose: If a dose is missed, it should be administered as soon as possible within 96 hours (4 days). If more than 96 hours have passed, the missed dose should be skipped and the next dose administered at the regular time.

Precautionary measures

Tirzepatide is a suitable treatment for most people who need pharmacological support for weight loss. However, there are some contraindications for this weight control medication, including:

  • Personal or family history of medullary thyroid carcinoma
  • Patients with Multiple Endocrine Neoplasia syndrome type 2
  • Known severe hypersensitivity to tirzepatide
  • Women who are pregnant, breastfeeding, or planning a pregnancy
  • Persons taking another GLP-1 agonist such as semaglutide or liraglutide
  • Persons with type 1 diabetes mellitus
  • Persons with a history of pancreatitis. If patients suspect they might have pancreatitis, they should discontinue the medication immediately.

Side effects

Very common (10% or more of patients):

  • Nausea (up to 18%)
  • Diarrhea (up to 17%)
  • Reduced appetite (up to 11%)
  • Nasopharyngitis (cold symptoms, up to 10.5%)
  • Hypoglycemia (especially when used concomitantly with insulin or sulfonylureas, up to 19%)

Common (1% to 10% of patients):

  • Vomiting
  • Constipation
  • Abdominal pain
  • Dyspepsia (digestive disorders)
  • Eructation (burping)
  • Bloating
  • Gastroesophageal reflux disease (GERD)
  • Injection site reactions (e.g., pain, redness)
  • Fatigue
  • Hyperglycemia
  • Hypersensitivity reactions (e.g., urticaria, eczema)

Rare (0.1% to 1% of patients):

  • Cholelithiasis (gallstones)
  • Acute pancreatitis
  • Elevated serum pancreatic enzymes (amylase, lipase)
  • Acute gallbladder disease (including biliary colic and cholecystectomy)

Rare and post-marketing reports:

  • Anaphylaxis
  • Angioedema
  • Acute kidney failure (especially in patients with pre-existing kidney disease)
  • Thyroid tumors (especially in patients with a history of medullary thyroid carcinoma)

Storage

  • Store tirzepatide in the refrigerator at 2°C to 8°C.
  • Do not freeze the medication; discard if frozen.
  • Keep the medication in its original packaging to protect it from light.
  • If necessary, tirzepatide can be stored at room temperature (up to 30°C) for up to 21 days.
  • Do not return to the refrigerator after storage at room temperature.
  • Keep the pre-filled pen in its original packaging until use.
  • Dispose of the pen properly after use according to local regulations.